ConductScience.org, home

Paper5118468

Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.

Medoff G and 2 others. Proc Soc Exp Biol Med, 1971. Cited by 216 papers, by iCite.

Cite this record

ConductScience Library. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Papers, record 5118468. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5118468

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.
PubMed
Journal
Proc Soc Exp Biol Med
PubMed
Year
1971
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
216
iCite
Relative citation ratio, by iCite
9.41
iCite
Revised in PubMed
2020-09-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Medoff GG
2Comfort MM
3Kobayashi GSG S

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Amphotericin BMajor topic
Antifungal AgentsMajor topic
CytosineMajor topic
Drug SynergismMajor topic
Candida
Cell Count
Cells, Cultured
Cryptococcus
Drug Resistance, Microbial
Fluorine
Saccharomyces

Source PubMed

Download CSV of topics

Cited by52

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 216 citations.

PMIDTitleJournalYearIn PapersSource
40693795Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery.mBio2025https://conductscience.org/library/papers/40693795PubMed
34151414Drug repurposing strategies in the development of potential antifungal agents.Appl Microbiol Biotechnol2021https://conductscience.org/library/papers/34151414PubMed
28205003Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.Pharm Res2017https://conductscience.org/library/papers/28205003PubMed
25026870Yeast central nervous system infection in a critically ill patient: a case report.J Med Case Rep2014https://conductscience.org/library/papers/25026870PubMed
24595533Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Clin Pharmacokinet2014https://conductscience.org/library/papers/24595533PubMed
17043122Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.Antimicrob Agents Chemother2007https://conductscience.org/library/papers/17043122PubMed
16377675Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16377675PubMed
16033288Antifungal combination therapy: clinical potential.Drugs2005https://conductscience.org/library/papers/16033288PubMed
15830474In vitro and in vivo activity of 5-fluorocytosine on Acanthamoeba.Antimicrob Agents Chemother1974https://conductscience.org/library/papers/15830474PubMed
15015031Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.Eur J Clin Microbiol Infect Dis2004https://conductscience.org/library/papers/15015031PubMed
14982754Combination antifungal therapy.Antimicrob Agents Chemother2004https://conductscience.org/library/papers/14982754PubMed
10949601New antifungal therapy in ophthalmology.Trans Am Ophthalmol Soc1973https://conductscience.org/library/papers/10949601PubMed
10515900Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.Clin Microbiol Rev1999https://conductscience.org/library/papers/10515900PubMed
8964037History of medical mycology in the united states.Clin Microbiol Rev1996https://conductscience.org/library/papers/8964037PubMed
8585726In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/8585726PubMed
8573294Lipid formulations of amphotericin B. Less toxicity but at what economic cost?Drug Saf1995https://conductscience.org/library/papers/8573294PubMed
7385824Management of central nervous system cryptococcosis.West J Med1980https://conductscience.org/library/papers/7385824PubMed
6301590Therapy of fungal infections.Bull N Y Acad Med1982https://conductscience.org/library/papers/6301590PubMed
6299182Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans.Antimicrob Agents Chemother1983https://conductscience.org/library/papers/6299182PubMed
6295266Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6295266PubMed

See all 52 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/5118468

GET https://conductscience.org/api/papers/v1/5118468/cited_by?page=2